$AKTX News

Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

Akari Therapeutics CEO Highlights ASCO Data Demonstrating Synergy Of AKTX-101 With Adagasrib In KRAS-Driven Cancers In Virtual Investor "What This Means" Segment

Why Akari Therapeutics Stock Is Falling On Tuesday?

Akari Therapeutics Stock Jumps On Promising Preclinical Data

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Akari Therapeutics' AKTX-101 Shows Synergistic Preclinical Cytotoxicity With KRAS Inhibitor In KRAS-Mutant Pancreatic Cancer Models, Highlighting RNA Splicing Payload Advantage

Akari Therapeutics Announces $5.5 Million Private Placement Offering

Akari Therapeutics Commences $5.5M Private Placement

Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase

Why Akari Therapeutics Stock Is Surging On Thursday?

Akari Therapeutics Granted European Patent For Proprietary ADC Payload Platform Technology

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

Akari Therapeutics Announces Abstract Acceptance For Online Publication At American Society Of Clinical Oncology Annual Meeting 2026

Maxim Sees High Risk Profile for Akari Therapeutics, plc (AKTX) Amid Capital Needs

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Akari Therapeutics' AKTX-101 Shows Superior Preclinical Potency Versus Leading TROP2 ADCs Across Bladder, Lung, And Breast Cancer Models

Akari Therapeutics downgraded to Hold from Buy at Maxim